Department of Medicine, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, 121 Boulevard de Waterloo, 1000 Bruxelles, Belgium.
Crit Rev Oncol Hematol. 2012 Jan;81(1):49-57. doi: 10.1016/j.critrevonc.2011.02.002. Epub 2011 Mar 10.
NSCLC, a tobacco-caused disease which is therefore highly preventable, is responsible for about 30% of all cancer deaths. Improvements in terms of survival have been overall disappointing. A major advance has been the demonstration of the value of platinum-based chemotherapy, not only for advanced disease, but also in the adjuvant and neoadjuvant settings. The favorable impact of second line therapy has been established as well. The most exciting recent development consists in the effective use of biological targeted therapies, namely the EGFR inhibitors. In selected groups of patients, these agents can be used successfully for first line or second line therapy. It is likely that other biologically targeted therapies will be developed in a near future. These progresses will lead hopefully to a more personalized and effective treatment of NSCLC.
非小细胞肺癌（NSCLC）是一种由烟草引起的疾病，因此具有高度可预防性，它导致了约 30%的所有癌症死亡。在生存方面的改善总体上令人失望。一个主要的进展是证明了基于铂的化疗的价值，不仅在晚期疾病中，而且在辅助和新辅助治疗中也是如此。二线治疗的有利影响也已得到证实。最近最令人兴奋的发展是生物靶向治疗的有效应用，即 EGFR 抑制剂。在某些特定的患者群体中，这些药物可成功用于一线或二线治疗。在不久的将来，可能会开发出其他生物靶向治疗方法。这些进展有望为 NSCLC 提供更个体化和更有效的治疗。
